BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 9363871)

  • 1. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer.
    Stadler WM; Kuzel T; Roth B; Raghavan D; Dorr FA
    J Clin Oncol; 1997 Nov; 15(11):3394-8. PubMed ID: 9363871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer.
    Moore MJ; Tannock IF; Ernst DS; Huan S; Murray N
    J Clin Oncol; 1997 Dec; 15(12):3441-5. PubMed ID: 9396395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer.
    Galsky MD; Hahn NM; Powles T; Hellerstedt BA; Lerner SP; Gardner TA; Yu M; O'Rourke M; Vogelzang NJ; Kocs D; McKenney SA; Melnyk AM; Hutson TE; Rauch M; Wang Y; Asmar L; Sonpavde G
    Clin Genitourin Cancer; 2013 Jun; 11(2):175-81. PubMed ID: 23228446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
    Shelley M; Cleves A; Wilt TJ; Mason M
    Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined chemoradiotherapy with gemcitabine in patients with locally advanced inoperable transitional cell carcinoma of the urinary bladder and/or in patients ineligible for surgery: a phase I trial.
    De Santis M; Bachner M; Cerveny M; Kametriser G; Steininger T; Königsberg R; Schratter-Sehn A; Sedlmayer F; Dittrich C
    Ann Oncol; 2014 Sep; 25(9):1789-1794. PubMed ID: 24936582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium.
    von der Maase H; Lehmann J; Gravis G; Joensuu H; Geertsen PF; Gough J; Chen G; Kania M
    Ann Oncol; 2006 Oct; 17(10):1533-8. PubMed ID: 16873433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder.
    Dalbagni G; Russo P; Sheinfeld J; Mazumdar M; Tong W; Rabbani F; Donat MS; Herr HW; Sogani P; dePalma D; Bajorin D
    J Clin Oncol; 2002 Aug; 20(15):3193-8. PubMed ID: 12149290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxic epidermal necrolysis associated with gemcitabine therapy in a patient with metastatic transitional cell carcinoma of the bladder.
    Mermershtain W; Cohen AD; Lazarev I; Grunwald M; Ariad S
    J Chemother; 2003 Oct; 15(5):510-1. PubMed ID: 14598945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine and other new chemotherapeutic agents for the treatment of metastatic bladder cancer.
    Vogelzang NJ; Stadler WM
    Urology; 1999 Feb; 53(2):243-50. PubMed ID: 9933034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-agent gemcitabine in previously untreated elderly patients with advanced bladder carcinoma: response to treatment and correlation with the comprehensive geriatric assessment.
    Castagneto B; Zai S; Marenco D; Bertetto O; Repetto L; Scaltriti L; Mencoboni M; Ferraris V; Botta M
    Oncology; 2004; 67(1):27-32. PubMed ID: 15459492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Gemcitabine in advanced bladder cancer].
    Lehmann J; Retz M; Lippert C; Albers P; Stöckle M
    Urologe A; 2003 Jan; 42(1):63-77. PubMed ID: 12574885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The efficacy and toxicity of gemcitabine and cisplatin chemotherapy in advanced/metastatic bladder urothelial carcinoma].
    Gunlusoy B; Arslan M; Vardar E; Degirmenci T; Kara C; Ceylan Y; Kozacıoğlu Z
    Actas Urol Esp; 2012 Oct; 36(9):515-20. PubMed ID: 22819345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasiblity study of gemcitabine and cisplatin administered every two weeks in patients with advanced urothelial tumors and impaired renal function.
    Carles J; Suárez C; Mesía C; Nogué M; Font A; Doménech M; Suárez M; Tusquets I; Gallén M; Albanell J; Fabregat X
    Clin Transl Oncol; 2006 Oct; 8(10):755-7. PubMed ID: 17074675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Toxicity of intravesical gemcitabine in superficial bladder cancer treatment].
    Beardo Villar P; Gamaza Martínez R; Gavira Moreno R
    Farm Hosp; 2014 May; 38(3):249-51. PubMed ID: 24951911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group.
    Moore MJ; Winquist EW; Murray N; Tannock IF; Huan S; Bennett K; Walsh W; Seymour L
    J Clin Oncol; 1999 Sep; 17(9):2876-81. PubMed ID: 10561365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective quality-of-life assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategy.
    Herman JM; Smith DC; Montie J; Hayman JA; Sullivan MA; Kent E; Griffith KA; Esper P; Sandler HM
    Urology; 2004 Jul; 64(1):69-73. PubMed ID: 15245938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial.
    von der Maase H; Andersen L; Crinò L; Weinknecht S; Dogliotti L
    Ann Oncol; 1999 Dec; 10(12):1461-5. PubMed ID: 10643537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single agent 2',2'-difluorodeoxycytidine in the treatment of metastatic urothelial carcinoma: a phase II study.
    Gebbia V; Testa A; Borsellino N; Mauceri G; Varvara F; Tirrito ML; Sambataro D; Fallica G
    Clin Ter; 1999; 150(1):11-5. PubMed ID: 10367539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II studies of gemcitabine for non-small cell lung cancer in Japan.
    Fukuoka M; Takada M; Yokoyama A; Kurita Y; Niitani H
    Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-42-S7-46. PubMed ID: 9194479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancer.
    Artz A; Stadler WM; Vogelzang NJ; Zimmerman T; Ryan C
    Am J Clin Oncol; 2005 Apr; 28(2):109-13. PubMed ID: 15803001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.